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SUMMARY 
 
Background:  
This study is part of the Chronic Rhinosinusitis Epidemiology Study (CRES). The 
overarching aim is to determine factors that influence the onset and severity of chronic 
rhinosinusitis (CRS). The aim of this analysis is to determine whether those with CRS are 
more likely to report psychiatric morbidity and in particular mood disturbance compared 
with healthy controls.  
 
Methods: 
CRES consists of a study-specific questionnaire regarding demographic and 
socioeconomic factors and past medical history as well as a nasal symptom score (SNOT-
22) and SF-36 (QoL - quality of life tool). Both of these tools contain mental health or 
emotional well-being domains. Participants were specifically asked whether they had 
ever consulted with their General Practitioner for anxiety or depression. Questionnaires 
were distributed to patients with CRS attending ENT outpatient clinics at 30 centres 
across the United Kingdom from 2007-2013. Controls were also recruited at these sites. 
Patients were divided into subgroups of CRS according to the absence/presence of polyps 
(CRSsNPs/CRSwNPs) or allergic fungal rhinosinusitis (AFRS). 
 
 
Results:  
Consultations with a family physician for depression or anxiety were higher amongst 
those with CRS than controls, but this was only significant for those with CRSsNPs. 
Odds ratio (OR) for CRSsNPs vs controls, 1.89, p=0.001; OR for CRSwNPs 1.40, 
p=0.078. Patients with CRS showed significantly higher mental health morbidity than 
controls across the mental health and emotional wellbeing domains of the SF-36 and 
SNOT-22.  Mean difference in the mental health domain of SF-36 was 8.3 for CRSsNPs 
and 5.3 for CRSwNPs (p<0.001). For the emotional domain of SNOT-22, differences 
were 7.7 and 6.3 respectively (p<0.001). 
 
Conclusions:  
Depression and anxiety are significantly more common in patients with CRS compared to 
healthy controls, especially in those with CRSsNPs. This added mental health morbidity 
needs consideration when managing these patients in primary and secondary care 
settings. 
 
INTRODUCTION 
 
Chronic rhinosinusitis (CRS) is a common condition with a recent European study 
showing the prevalence of to be 10.9% across Europe which equates to 6.8 million 
Britons affected(Bachert, Van Bruaene et al. 2009).  The recent European Position Paper 
on Rhinosinusitis and Nasal Polyps 2012 (EPOS) (Fokkens, Lund et al. 2012), defines 
rhinosinusitis in adults as ‘inflammation of the nose and the paranasal sinuses 
characterised by two or more symptoms, one of which should be either nasal 
blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip) ± facial 
pain/pressure ± reduction or loss of smell and either endoscopic or CT findings of polyps, 
mucopus or mucosal oedema. Rhinosinusitis is considered ‘chronic’ if symptoms persist 
for > 12 weeks. CRS is currently subdivided into two main types – CRS with and without 
nasal polyps (CRSwNP and CRSsNP respectively), as exemplified by EPOS 2012 
(Fokkens, Lund et al. 2012) to broad phenotypes, with allergic fungal rhinosinusitis 
(AFRS) as a distinct subtype of CRSwNP, which is particularly severe and difficult to 
treat. 
 
Whilst diagnosis and treatment of CRS is largely based on nasal symptoms, it is known 
that CRS has a much wider effect on health. Consultations for CRS both in Primary Care 
and ENT tend to focus on the symptoms used to make a clinical diagnosis (Fokkens, 
Lund et al. 2012) rather than a more holistic evaluation of patient well-being including 
mental health (Galderisi, Heinz et al 2015). A previous study of 158 patients has 
suggested significant morbidity in CRS with quality of life scores worse than amongst 
those with other chronic diseases such as lower back pain (Gliklich and Metson 1995). 
Since CRS primarily affects those aged 40-60 years, the significant effect on an 
individual’s functioning and productivity also has an impact in the workplace. CRS has 
been identified as one of the top ten most costly diseases for US employers (Goetzel, 
Hawkins et al. 2003). Qualitative interviews with patients with CRS have found that 
those affected describe low mood, poor sleep and even suicidal ideation (Erskine, 
Verkerk et al. 2015). EPOS states under the heading ‘Research Needs’ that studies are 
required to ‘investigate the impact of psychological problems such as depression, stress 
exposure and anxiety’ (Fokkens, Lund et al. 2012) .  
 
The overarching aim of the CRS Epidemiology Study (CRES) was to identify differences 
in socio-economic variables between patients with CRS and healthy controls to aid better 
understanding of medical and non-medical factors contributing to the development or 
worsening of CRS. The purpose of this study is to consider the differences in psychiatric 
morbidity between those with different types of CRS and controls using several different 
self-reported measures of mental health and emotional well-being. 
MATERIALS AND METHODS 
 
Study Design and Setting 
CRES was approved by the Oxford C Research Ethics Committee, sponsored by the 
University of East Anglia (UEA) and funded by the Anthony Long and Bernice Bibby 
Trusts. Following a pilot study of the questionnaire in 2006, the study commenced 
recruitment in ENT departments of the East Anglia region (East of England Deanery) of 
the UK in 2007. Following elevation to the National Institute of Health Research Clinical 
Research Network Portfolio in 2012, a total of 30 sites from around the UK (including 
Wales and Scotland) joined the study which ran between 2007 and 2013. The study 
specific questionnaire was anonymous and therefore consent was implied through 
participation. Participant information leaflets were provided.   
 
Participants 
Patients presenting to secondary care outpatient clinics and diagnosed with CRS by an 
ENT surgeon, as defined by the criteria laid out in the European Position Paper on 
Rhinosinusitis and Nasal Polyps (Fokkens, Lund et al. 2012) were invited to participate 
in the study regardless of symptom or disease severity or duration, and regardless of any 
prior interventions. Participants may therefore have been seen by ENT for the first time 
when they were recruited or they could have had treatment previously. Patients were 
classified by sub group of CRS (CRSsNPs, CRSwNPs or allergic fungal rhinosinusitis 
(AFRS) by a clinician prior to completion of the questionnaire using the EPOS 
definitions for with or without polyps (using endoscopic and/or radiological 
confirmation). Patients placed in the AFRS category met the Bent and Kuhn criteria 
(Bent and Kuhn 1994) or the St Paul’s Sinus Centre modification of this (Philpott, Javer 
et al. 2011). Controls included family and friends of those attending ENT outpatient 
clinics and hospital staff who had no diagnosis of nose or sinus problems and had not 
been admitted to hospital in the previous 12 months.  
 
Participants taking part in qualitative interviews were all recruited from one centre. 
Methodology and results of these studies are published elsewhere (Erskine, Notley et al. , 
Erskine, Verkerk et al. 2015) 
 
Variables and data sources 
The study questionnaire was designed with the input of the East of England Research 
Design Service and included study specific questions relating to socio-economic, 
environmental and medical co-morbid variables as well as the validated Short Form 36 
Quality of Life (QoL) measure (SF-36) (18) measure and the Sino-Nasal Outcome Test 
questionnaire (SNOT-22)(19). In this analysis the mental health domain of SF-36 and the 
emotional domain for SNOT-22 were also used. SNOT-22 asks 22 symptoms of CRS, 
both nasal and non-nasal, these are scored from 0 to 5 for severity, so the total is out of 
110. The emotional domain of SNOT-22 includes fatigue, reduced productivity, reduced 
concentration, frustration/restlessness/irritability, sadness and embarrassment. 
Participants were additionally asked whether they had consulted their GP for anxiety or 
depression. 
 
Statistical analysis 
The participant characteristics are described using mean and standard deviation for 
continuous measures and number and percentage for categorical variables. Both disease 
groups are compared to control in terms of proportion with any facial pain, anxiety, 
depression or anxiety and depression using logistic regression, using odds ratios to 
compare the disease groups to control. They were also compared using regression for 
Mental Health SF-36, SNOT-22 emotion, SF-36 total and SNOT-22 total, using the mean 
difference to compare the disease groups to control. Results were firstly unadjusted, then 
adjusted for age and sex. The mean difference was additionally adjusted for consultation 
for anxiety or depression. 
 
 
 
RESULTS 
A total of 1,470 participants were recruited as shown in table 1. The overall recruitment 
was 66% of those invited to participate. Information on reasons for non-participation is 
not available. 
 
Table 1: Demographic information of CRS subgroups 
 
 
1,464 participants included sufficient information to analyse consultations with anxiety 
and depression. All measures of mental well-being are shown in table 2. 
 
 
Table 2: Mental well-being variables by CRS group  
 
 
Differences between those with CRS and controls were found in rates of consultation 
with GP for anxiety and depression. Those with CRSsNPs reported significantly higher 
rates of consultation for both anxiety and depression than controls.  Those with CRSwNP 
reported higher rates of consultation for depression, but this was not significant. 
Differences were found in total and mental health SF-36 score and total and emotional 
domain of SNOT-22 score, with those with CRS scoring more poorly than controls, and 
those with CRSsNPs scoring more poorly than those with CRSwNP in SF-36 and SNOT-
22 overall and in both the mental health and emotional domains and in. Table 3 show 
odds ratios for these variables.  
 
 
Table 3: Differences in psychiatric morbidity between subgroups  
 
Those with CRSsNPs scored significantly more poorly than controls across all measures 
of mental and emotional health. Those with CRSwNPs scored more highly on the 
mental/emotional domains of SF-36 and SNOT-22.  
 Differences in scores for mental health and emotional domains as well as total SF-36 and 
SNOT-22 persist despite adjusting for consultation with GP for anxiety and depression 
(table 4). 
 
Table 4: Differences in SF-36 and SNOT-22 after adjustment for gender, age and 
anxiety/depression 
DISCUSSION 
Key Results 
All measures of anxiety and depression in this cohort were higher amongst those with 
CRSsNPs compared with controls. Mental health and emotional well-being measures 
were higher amongst those with CRSwNP than controls. Those with CRsNPs had scored 
more poorly than those with CRSwNPs. Differences in mental health and well-being 
persisted despite adjusting for consultation with GP for anxiety and depression. 
 
Strengths and limitations 
The study is self-reported, although there is no reason for any subgroup to over-report 
symptoms compared to any other. 
 
A strength of the study is the ability to triangulate information about psychiatric 
morbidity from three sources; SF-36, SNOT-22 and GP consultation.  
 
The study has focused on CRS patients in a secondary care setting, however it is 
recognised that the larger burden of CRS is seen in a primary care setting. We do not 
have data on disease severity according to objective measures such as the Lund Mackay 
score or endoscopic grading due to the anonymous self-reported nature of the study. 
These are known to be poor predictors of symptom severity(Hopkins, Browne et al. 
2007) Participants were examined (via endoscopy) to establish subgroup prior to entry 
into the study but no further assessment of clinical disease was taken. We do not know 
whether those who have seen a GP for anxiety or depression have ongoing symptoms. 
  
Interpretation 
Any person with chronic disease is likely to score less favourably for mental health/ 
emotional well-being since they will often need to adjust their lifestyle, hopes and even 
employment to accommodate their illness (Turner and Kelly 2000); given that CRS does 
not give rise to a specific disability, the extent of the morbidity it is associated with may 
be overlooked by clinicians (Erskine, Notley et al. , Erskine, Verkerk et al. 2015), which 
in itself may lead to increased levels of distress. Previous smaller studies of 63 rhinitis 
patients and 143 CRS patients respectively have also found that such patients have 
increased levels of anxiety and depression (Ryden O, Andersson B et al. 2004, Wasan, 
Fernandez et al. 2007). The causal association is not well-understood; depression and 
anxiety may amplify symptoms of CRS or be the consequence of living with CRS, or it 
may be that the co-morbid anxiety and depression are epiphenomena. These results show 
that the psychological co-morbidity associated with CRS is significant. Such co-
morbidities should be taken into account when managing patients. There is good 
evidence from other areas that appropriate treatment of co-morbid mental disorder is 
likely to improve outcomes of physical disorders (Moussavi, Chatterji et al. 2007). 
 
Both state anxiety (defined as fear, tension, and increased arousal induced temporarily by 
specific situations perceived as threatening) and trait anxiety (a predisposition to stress 
and worry) have been found to be higher amongst those with both allergic rhinitis (IgE 
mediated) and vasomotor rhinitis (Vidian nerve hypersensitivity) than controls 
(Addolorato, Ancona et al. 1999) and could reflect autonomic nervous system (ANS) 
dysfunction. The nose has a rich and complex nerve supply which is experienced on a 
routine basis; rhinorrhoea in cold weather or when eating spicy foods. The ANS has a 
role in altering the nasal airway during postural change(Ko, Kuo et al. 2008)  but the 
relevance of ANS dysfunction in the generation of nasal symptoms remains little studied. 
It has been evaluated in few previous series totalling fewer than 30 patients (Ishman, 
Martin et al. 2007). The main differences between patients and controls were that 
sudomotor, cardiovagal and adrenergic subscores were all significantly more abnormal 
amongst patients than controls, as were overall ANS scores.  
 
Personality traits, in particular ‘type A’ personality and anxiety are implicated in the 
development of cardiovascular disease, this may be explained by abnormal sympathetic 
nervous activity in response to stressors (Schroeder, Narkiewicz et al. 2000). Similar 
mechanisms may occur in the nasal airway, meaning that those who are more anxious 
already may be more likely to experience nasal symptoms such as congestion and 
rhinorrhoea. Fatigue is also a frequent concomitant symptom of ANS dysfunction and is 
regularly found in CRS patients.  ANS dysfunction may therefore contribute to the 
several components of CRS symptom generation, including: 
 1. Predisposing factors - Personality and or other factors which set ‘baseline’ ANS 
activity in an individual 
 2. Precipitating factors – Responses to environmental triggers and state anxiety 
 3. Perpetuating factors – ANS dysfunction may feed into low mood, anxiety and 
fatigue  
   
Stress and infections are independently associated with asthma development and 
exacerbation. There is evidence that stress hormones can alter immune processes, induce 
inflammation, and increase susceptibility to infection in those with asthma; T-Helper 
cells have particularly been implicated. Additionally, prolonged psychological stress is 
thought to predispose to respiratory infections in asthmatics (Trueba and Ritz 2013). CRS 
has a very complex aetiology, with bacteria, viruses, fungi, immune dysfunction, atopy 
and genetic predisposition all implicated; similar interactions with infection and stress 
may also apply. 
 
The differences between those who have CRS with and without polyps are perhaps more 
complex to understand. Our results show that those without polyps are more likely to 
consult with their GP and also tend to score more poorly on the mental and emotional 
scales, as well as total SF-36 and SNOT-22. Clinically, those with nasal polyps and in 
particular those with AFRS (where nasal polyps are also present) are often considered to 
have more severe disease with more obvious pathology. CRS is often considered to be a 
spectrum of disease from CRSsNP to AFRS. It could be logical to think therefore that 
patients with nasal polyps would experience more significant negative impact on their 
emotional well-being as a consequence of the physical manifestations of polyps, but this 
is not apparent in our data. Mental health scores in those with CRS have been found to 
correlate with subjective symptom scores (Nanayakkara, Igwe et al. 2013). Data from 
CRES found that when using total SNOT-22 scores, those with polyps scored more 
highly for nasal symptoms than those without (A cross sectional cohort study of Quality 
of life in CRS in the UK; a comparison between CRS subtypes, Rhinology journal – 
under review(Philpott, Erskine et al. 2016), although it is well known that measurements 
of individual objective parameters of disease such as peak nasal inspiratory flow rates or 
scoring the severity of CT scans (Lund Mackay score) do not correlate well with patients’ 
own self-reported symptom scores (Hopkins, Browne et al. 2007). Our results find that 
emotional well-being is worse amongst those without nasal polyps. One explanation 
could be that patients with polyps may have an expectation that these can be removed 
facilitating a ‘cure’. Some ‘sinonasal’ symptoms such as facial pain and headache have a 
vast possible aetiology and are well known to be associated with anxiety states; they are 
also found more frequently in patients with CRSsNPs than in those with polyps (found in 
our own study) (Durr, Desrosiers et al. 2001).  
 
It has been suggested that certain clinical variables such as age, culture, expectations and 
mental and physical health may influence patient’s reporting of their symptoms and 
consequently modify disease severity (Wilson and Cleary 1995). CRS patients with 
depression are known to report significantly worse pain and energy levels, and difficulty 
with daily activities when compared with a control group of CRS patients without 
depression (Brandsted and Sindwani 2007). Symptoms such as fatigue are also more 
likely to be reported in patients with depression. Studies have found dynamic changes in 
mu-opioid neurotransmission in response to an experimentally induced negative affective 
state which support a physiological basis for somatic amplification in patients with mood 
disturbance (Zubieta, Ketter et al. 2003, Wasan, Fernandez et al. 2007, Wasan, Fernandez 
et al. 2007). Pre-existing or concurrent psychiatric comorbidity may therefore affect 
symptom reporting, with those with psychiatric co-morbidities known to report elevated 
symptom scores (Wasan, Fernandez et al. 2007). In our study, differences in mental 
health and well-being persisted, despite adjusting for consultation with GP for anxiety 
and depression, with those with CRS scoring significantly more poorly than controls. So 
even those with no diagnosis of depression or anxiety are still reporting decreased mental 
health and emotional well-being. This should be taken into consideration when managing 
patients with mood disturbance and CRS.  
 
Clinically, the association between mood disturbance and CRS is important for many 
reasons. Depression or anxiety symptoms may decrease motivation to seek medical help 
or adhere to treatment plans (Turner and Kelly 2000). Many treatments for CRS involve 
nasal douching or application of nasal sprays or drops which can be time-consuming and 
inconvenient (Erskine, Notley et al.) and may be more challenging to stick to than simply 
taking a tablet. Oral steroids are frequently used in the management of nasal polyps and 
are known to affect mood in many ways; clinicians should be careful to discuss these 
mood-altering effects in those who may already have a mood disturbance. It may be 
necessary to screen those whose symptoms are particularly bothersome for anxiety or 
depression diagnoses, for example the Hospital Anxiety and Depression Score (HADS), 
to see whether such symptoms require treatment over and above management of nasal 
symptoms. Simply taking note of a patient’s symptoms may be beneficial (Erskine, 
Notley et al. , Erskine, Verkerk et al. 2015). Other simpler measure such as writing down 
experiences have been found to bring about measurable physiological improvements in 
patients with comparable chronic conditions such as asthma (Smyth, Stone et al. 1999).  
 
Conclusion 
Our study has shown that those with CRS experience poorer mental well-being than 
healthy controls. Additionally, those with CRSsNPs score worse than those with polypoid 
disease. This is the largest UK study to show such a difference between these phenotypes, 
although anecdotally many clinicians have seen such a phenomenon in clinical practice. 
Our results should influence management strategies for patients with different nasal 
pathologies by highlighting the importance of considering the non-nasal sequelae and 
associated symptoms of CRS particularly amongst those with CRSsNPs.  
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Table 1: Demographic information of CRS subgroups 
 
  Controls CRSsNP CRSwNP AFRS 
Participants 221 553 651 45 
Females 143 (68.4%) 259 (53.1%) 185 (32.2%) 19 (43.2%) 
Mean Age 
(s.d) 
47.3 (14.9) 51.8 (15.3) 56.0 (14.6) 56.1 (12.7) 
Range 19-82 18-84 17-102 20-76 
 
Table 2: Mental well-being variables by CRS group  
 
  Controls   % CRSsNP  % CRSwNP/AFRS  % 
Total  221  551  692  
Consultation 
with GP Anxiety 
35 15.84 128 23.23 112 16.21 
 Depression 32 14.48 139 25.23 139 20.09 
 Anxiety or 
depression 
43 19.46 173 31.40 175 25.29 
Any facial 
pain  
28 13.86 363 70.90 388 57.82 
  Mean S.D Mean  S.D Mean  S.D 
Mental health SF-36 77.91  14.99 69.58 19.82 72.65 18.23 
SNOT-22 (emotional 
domain) 
3.66 5.51 11.37 7.64 9.92 7.46 
SF-36 total 80.75 15.12 65.92 21.41 69.28 19.62 
SNOT-22 total 12.11 13.95 45.67 21.05 44.41 21.62 
 
Table 3: Differences in psychiatric morbidity between subgroups  
 
 CRSsNP vs control 
 
 
 
CRSwNP vs control 
 
 Unadjusted Age-sex adjusted Unadjusted Age-sex adjusted 
 
Odds ratio p-value Odds ratio p-value Odds ratio 
p-
value 
Odds ratio 
p-
value 
Anxiety 
1.61 (1.07,2.43) 0.024 1.83 (1.16,2.88) 0.009 
1.03 
(0.68,1.56) 
0.896 
1.38 
(0.86,2.20) 
0.183 
Depression 
1.99 (1.31,3.04) 0.001 2.25 (1.41,3.57) 0.001 
1.48 
(0.98,2.26) 
0.064 
2.03 
(1.26,3.25) 
0.003 
Anxiety or 
depression 
1.89 (1.30,2.77) 0.001 2.14 (1.41,3.24) <0.001 
1.40 
(0.96,2.04) 
0.078 
1.88 
(1.23,2.87) 
0.004 
Any facial pain 
15.14 (9.73,23.56) <0.001 
27.36 
(16.31,45.90) 
<0.001 
8.52 
(5.56,13.06) 
<0.001 
18.46 
(11.02,30.92) 
<0.001 
 
Mean difference p-value Mean difference p-value 
Mean 
difference 
p-
value 
  
Mental health -8.33 (-11.22,- <0.001 -9.39 (-12.39,- <0.001 -5.26 (-8.06,- <0.001 -8.49 (- <0.001 
SF-36 5.44) 6.39) 2.46) 11.49,-5.48) 
Snot22 
(emotion) 
7.71 (6.53,8.89) <0.001 8.28 (7.06,9.50) <0.001 
6.26 
(5.12,7.40) 
<0.001 
7.50 
(6.28,8.71) 
<0.001 
SF-36 -14.84 (-17.94,-
11.74) 
<0.001 
-15.32 (-18.56,-
12.08) 
<0.001 
-11.48 (-
14.48,-8.48) 
<0.001 
-13.30 (-
16.55,-10.05) 
<0.001 
SNOT-22 33.57 
(30.21,36.92) 
<0.001 
35.99 
(32.50,39.47) 
<0.001 
32.30 
(29.07,35.54) 
<0.001 
36.81 
(33.33,40.30) 
<0.001 
 
 
 
 
 
 
Table 4: Differences in SF-36 and SNOT-22 after adjustment for gender, age and 
anxiety/depression  
 
 CRSsNP vs 
control 
 % 
CRSwNP vs 
control 
 % 
 Mean 
difference 
p-value 
Mean 
difference 
p-value 
Mental health SF-36  
-7.00 (-9.72,-
4.28) 
<0.001 
 
-6.48 (-9.21,-
3.76) 
<0.001 
Snot22 (emotion) 7.50 (6.34,8.66) <0.001 6.86 (5.70,8.01) <0.001 
SF-36 -13.08 (-16.12,-
10.05) 
<0.001 
-11.43 (-14.47,-
8.40) 
<0.001 
SNOT-22 34.45 
(31.05,37.86) 
<0.001 
35.51 
(32.12,38.90) 
<0.001 
 
